China's Brii Biosciences gains on positive data on its COVID treatment

Brii Biosciences

27/07/2022 08:07

** Shares of infectious disease therapies developer Brii
Biosciences Ltd  2137.HK  jump 9.1% to HK$10.36, the biggest
intraday pct gain since July 11 
    ** Stock hits the highest since July 22 and on course for a
second session of gains; stock is the third-biggest pct gainer
in Hang Seng Composite Index  .HSCI 
    ** The Beijing-based co announces positive data confirming
its long-acting COVID-19 monoclonal antibody therapy -  
amubarvimab/romlusevimab combination, retains neutralizing
activity against Omicron BA.4/5 and BA.2.12.1 SARS-CoV-2
subvariants  urn:newsml:reuters.com:*:nFWN2Z75L2
    ** Says based on human pharmacokinetic data gathered on the
amubarvimab/romlusevimab combination, exposures of intravenous
amubarvimab and romlusevimab are expected to remain above the
level required for neutralizing activity against Omicron BA.4/5
and BA.2.12.1 SARS-CoV-2 subvariants for COVID-19 treatment 
    ** Says the U.S. Food and Drug Administration is currently
reviewing the co's emergency use authorization application for
the amubarvimab/romlusevimab combination
    ** The Hang Seng healthcare index  .HSCIH  drops 2.3%, while
the Hang Seng Composite Index  .HSCI  and the benchmark Hang
Seng Index  .HSI  slip 1.4% each
    ** As of last close, stock down 71.1% this year
    
    
    

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))